Researchers studied 1,866 postmenopausal women and found that using bisphosphonate for more than one year helped reduce the risk of colorectal cancer by 59 percent. The bisphosphonate used by a majority of women was alendronate, sold under the brand name Fosamax and made available under a generic brand. The positive effect of taking bisphosphonate after the one-year mark was not as significant, according to the report.
Read the news report about bisphosphonate and CRC.
Read other coverage about colorectal cancer:
– 10 Recent Findings on GI Quality Issues
– Pricetag of Treating CRC: $14.1B
– USPSTF Advises Against CRC Screening for Individuals Older Than 85
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.